Elevated levels of PAX3 and cell proliferation genes are characteristic features of rhabdomyosarcoma (RMS). We hypothesize that the increased levels of these genes are stabilized due to downregulation of specific miRNAs. In this study, we show that downregulation of miR-1, -206 and -29 stabilizes the expression of PAX3 and CCND2 in both embryonal (ERMS) and alveolar (ARMS) RMS types. Ectopic expression of miR-1 and 206 in JR1, an ERMS cell line, show significant downregulation of PAX3 protein expression, whereas overexpression of these miRNAs in Rh30, an ARMS cell line, did not show any effect in PAX3 protein levels. In ARMS, PAX3 forms a fusion transcript with FOXO1 and the resultant loss of PAX3 3 0 UTR in the fusion transcript indicate an oncogenic mechanism to evade miRNA-mediated regulation of PAX3. Further, we show that miR-1, -206 and -29 can regulate the expression of CCND2, a cell cycle gene. In addition to CCND2, miR-29 also targets E2F7, another cell cycle regulator. Cell function analysis shows that overexpression of miR-29 downregulates the expression of these cell cycle genes, induces partial G1 arrest leading to decreased cell proliferation. Taken together our data suggest that the RMS state is stabilized by the deregulation of multiple miRNAs and their target genes, supporting a tumor suppressor role for these miRNA.
Rhabdomyosarcoma (RMS) is a malignant striated muscle tumor that accounts for B3% of all childhood cancers. 1 RMS arises from primitive muscle cells and tumors show varying degrees of skeletal muscle differentiation that serves to define their classification as either embryonal (ERMS) or alveolar (ARMS) types. 2, 3 ERMS, the most common type has features of embryonic muscle and are generally associated with favorable prognosis. In contrast, ARMS display poor muscle differentiation and are associated with poor outcomes. 4 Most ARMS cases are characterized by chromosomal translocation t(2;13) or t(1;13) involving genes PAX3-FKHR or PAX7-FKHR, respectively. 5 Regulatory disruptions in growth and differentiation pathways of myogenic precursor cells have been implicated in RMS development. Genes involved with muscle cell differentiation and cell proliferation have been associated with RMS development and metastasis. [6] [7] [8] [9] [10] [11] Gene expression profiles comparing PAX-FOXO1-positive ARMS vs translocation-negative ERMS have identified genes relevant to tumorigenic process of ARMS and ERMS. 12 microRNAs (miRNAs) have been implicated in RMS. [13] [14] [15] miRNAs are small (18-22 nucleotides) evolutionarily conserved, non-coding RNAs that post-transcriptionally regulate gene expression through mRNA degradation, translation inhibition or chromatin-based silencing mechanisms. 16 Each miRNA can potentially regulate hundreds of targets either directly or indirectly. miRNAs have been shown to be deregulated in many types of cancers. 17 As a consequence, miRNAs from tumor tissue have been proposed for use in the diagnosis, classification and prognosis of tumors. 18, 19 Previous work in our lab has shown that miRNA expression profiles of ARMS and ERMS samples can be used to identify a misdiagnosed case. 13 miRNAs such as miR-1, -133, -206 and -29 that have been implicated in skeletal muscle proliferation and differentiation 20, 21 are undergoing investigation about their roles in RMS. Transient transfection of miR-1/206 into cultured RMS cells led to a significant decrease in cell growth and migration. 22 Further, exogenous expression of miR-206 promoted myogenic differentiation and blocked RMS growth in a xenotransplant mice model. 14 In our recent work, we have showed that many miRNAs including miR-29 family are significantly downregulated in RMS compared with normal skeletal muscle (NSM), 13 and that miR-183 is upregulated as an oncogene by targeting transcription factor EGR1, which in turn may affect the activation of tumor suppressor gene, PTEN. 23 Although miRNAs have been extensively studied in the context of muscle differentiation, the miRNA expression patterns in RMS and their role in tumorigenesis is not completely understood.
In this study, using a large series of RMS and NSM tissue samples, we show that ARMS and ERMS are characterized by combined perturbation of miRNA and mRNA expression relative to NSM. Further, using in vitro approaches, we functionally evaluated the role of miR-1 and -206 in the direct regulation of PAX3 in RMS. Additionally, we show that miR-29 can directly regulate both CCND2 and E2F7, genes implicated in cell cycle control, suggesting a potential tumor suppressor role for miR-29 in RMS. Our results support a model in which multiple perturbations of miRNA networks lead to deregulation of PAX3 and cell cycle genes involved in RMS tumorigenesis.
MATERIALS AND METHODS
Detailed methods including constructs and primers are given as Supplementary Information.
Tissue Samples
In all, 48 fresh frozen tumor and normal tissue samples (21 ARMS, 20 ERMS and 7 NSMs) were used in the analyses. RMS tumor tissues and normal muscle samples were obtained from the cooperative human tissue network and from the tissue procurement facility at the University of Minnesota, respectively. For three RMS cases (FT-261, -271 and -281), patient-matched normal muscle tissues were also available. The institutional review board approved this study. Basic clinical data of RMS samples are given in Supplementary Information 1.
miRNA and mRNA Expression Analysis Total RNA extraction and purification were followed as described previously. 13 miRNA expression profiles were generated for all the 48 RMS and NSM tissue samples (21 ARMS, 20 ERMS and 7 NSMs). We used Illumina Sentrix Array Matrix for miRNA expression profiling as previously described. 24 mRNA expression profiles of RMS and normal tissue samples were generated using Illumina human (HT-12) arrays, allowing high throughput expression profiling of 48 000 human RefSeq and UniGene annotated genes. 25 Statistical Analysis for miRNA and mRNA Profiling Data miRNA and mRNA fluorescence values were obtained from the Illumina detection system without background subtraction and were quantile normalized using GeneData Expressionist Software (Genedata, San Francisco, CA, USA). Principal component analyses (PCAs) were carried out directly on the quantile-normalized data. Both datasets were then further normalized to the average value obtained from the normal muscle tissue. Statistically significant genes were determined using two-group t-test. A P-value cutoff was required to be less than 0.001 and the data set was further filtered, and the ratio of the group median needed to be greater than two-fold for an RNA transcript to be included in the analyses. Ingenuity pathways analyses (http://www. ingenuity.com/) tool was used to determine functional enrichment and canonical pathway enrichment. B and H multiple testing-corrected P-values were used for functional enrichment analyses.
Quantitative Real-Time PCR miRNAs and mRNAs were analyzed using miScript PCR system (Qiagen, Valencia, CA, USA) on Light cycler 480 (Roche, Indianapolis, IN, USA), following the manufacturer's recommendations. miRNAs were quantified with U6 small RNA serving as normalization control, and mRNAs with GAPDH as reference control. The fold expression and statistical significance were calculated using 2 ÀDD Ct method. 26, 27 Cell Culture ARMS cells lines (Rh30 and Rh18), ERMS cell lines (JR1 and RD) and HEK293 were grown in Dulbecco's modified Eagle's Medium (DMEM, with 4 g/l glucose, 4 mM L-glutamine and 110 mg/l sodium pyruvate) (Hyclone, Logan, UT, USA) supplemented with 10% Fetal bovine serum (FBS, GIBCO) at 37 1C and 5% CO 2 . These RMS cell lines were authenticated by the presence of PAX3 or fusion PAX3-FOXO1 fusion proteins.
Reporter Constructs
Two sets of luciferase reporter systems, psiCHECK-2-based vectors (Promega, Madison, WI, USA) and 3 0 UTR-sGG vectors (SwitchGear, Menlo Park, CA, USA) were used. 3 0 UTR-sGG vectors with mutations in specific miRNAbinding region were constructed using QuickChange sitedirected mutagenesis kit (Stratagene, Santa Clara, CA, USA) following manufacturer's instructions. pGL4.73 (Promega) with a Renilla luciferase gene was co-transfected with all 3 0 UTR reporter vectors, working as an internal control to normalize transfection efficiency. Details of oligos used and mutation sites are given in Supplemental Method section.
Transfection and Luciferase Assay
Three kinds of transfection reagents were used; 1) DNA only transfection: Lipofectamine 2000 (Invitrogen) was used to transfect DNA (reporter vectors) into cells; 2) DNA and miRNA precursor co-transfection: Attractene Transfection Reagent was used to transfect DNA (200 ng) and miRNA precursor (10 nM) together into cells; 3) miRNA (Ambion, Austin, TX, USA) transfection: HiPerFect Transfection Reagent (Qiagen) was used to transfect microRNA precursors (10 nM), scrambled miRNA precursor, or pre-miR negative control #1 (10 nM). Dual-Luciferase Reporter Assay System (Promega) was used to perform dual-reporter assays using Synergy 2 (BioTek, Winooski, VT, USA).
Total RNA and Protein Isolation from Cultured Cells Culture media were changed after 24 hours of transfection. Total RNAs and proteins were extracted using mirVana PARIS kit (Ambion), 48 h after transfection.
Western Blotting
Standard western blot analysis was carried out using protein extracts from pre-or post-treated cells. The following antibodies were used; PAX3 (ab53571, Abcam), CCND2 (ab3085, Abcam), E2F7 (sc-66870, Santa Cruz), GAPDH (39-8600, Invitrogen) and goat anti-mouse IgG-AP (sc-2008) or goat anti-rabbit IgG-AP (sc-2034) was used as secondary antibody.
Apoptosis, Cell Cycle and Proliferation Assays
Vybrant apoptosis assay kit #8 (Molecular Probes, Eugene, OR, USA) was used to detect apoptosis. Cell cycle assay was conducted on cells resuspended with 2 mg/ml propidium iodide (PI) (MP Biomedicals, Solon, OH, USA) and 200 mg/ml RNase A (Qiagen) in PBS on FACSCalibur (BD Biosciences) and analyzed with Flowjo 7.5.5. Cell proliferation assay was done using CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega) according to manufacturer's instruction.
RESULTS miRNA Expression Patterns in ARMS and ERMS
Genome-wide miRNA expression profiling was performed on 41 RMS cases (21 ARMS and 20 ERMS) and compared with NSM (n ¼ 7). These 41 RMS cases represented various tumor stages and grades as indicated in Supplementary Information 1. Median age for both ARMS and ERMS patients was 6 years. Male gender representation for ARMS and ERMS was at 50% and 80%, respectively.
PCA of ARMS, ERMS and NSM miRNA profiling data revealed significant difference in miRNA profiles between normal and tumor tissues (Figure 1a ). We noticed a unique and overlapping miRNA expression pattern among and between ARMS and ERMS cases (Figures 1b and c) . First, we investigated the miRNAs that are commonly dysregulated in both ARMS and ERMS. The analysis revealed the presence of 235 miRNAs with P-value less than 0.001 and fold change 42 between NSM and RMS samples (Figure 1b) . The overexpressed miRNAs in RMS includes miR-183, -9 and -154. We also noticed a significant increase in expression of clusters of miRNAs from 14q32 locus (miR-136, -377, -154, -1185, -376a, -382) in both RMS types. On the other hand, the downregulated miRNAs in both types of RMS includes miR-1, -133, -29a-c, -144 and -150. The complete list of all the differentially expressed miRNAs in NSM and RMS are shown in Supplementary Information 2 and 2a. Next, we determined the miRNAs that are uniquely expressed in both RMS types. We identified 69 miRNAs with P-value o0.001 and fold change 42 between ERMS and ARMS samples (Figure 1c ). These differentially expressed miRNAs between ARMS and ERMS includes miR-509-3p, -598, -135a, -7, -513, -506, -514. The list of differentially expressed miRNAs between ARMS and ERMS is given in Supplementary  Information 3 and 3a .
miRNAs that are differentially expressed in RMS vs NSM were validated in a representative set of RMS patient samples via qRT-PCR (Figure 1d ). We also determined that RMS cell lines (JR1 and Rh30) maintained miRNA expression patterns observed in tumors (Figure 1d ) indicating that they may be suitable for functional analyses of dysregulated miRNAs (see below). When validating the microarray finding with qRT-PCR, we noticed that miR-1 and -206 were significantly downregulated compared with NSM (Figure 1d ), which were not detected via microarray. Signal intensity analyses for microarray heatmap reveal that signals from miR-1 and -206 are highly saturated in NSM and RMS tissue samples (as shown in supplementary Information 3, page1), which may explain why the downregulation of miR-1/-206 in RMS is missed by microarray. Similar saturation of miR-1/-206 was noticed with spotted miRNA microarrays in our earlier studies. 13 
Dysregulation of Muscle Differentiation Genes in RMS
To determine mRNAs that are deregulated in RMS, we carried out gene expression analysis in a subset of RMS cases. PCA of mRNA expression data showed clear segregation of tumors and normal muscle samples (Figure 2a) . Further, we performed unsupervised hierarchical clustering of the mRNA profiles. The majority of NSM clustered separately from tumor samples (Figure 2b ). However, one tumor-matched normal tissue sample (FT-262) collected from an ARMS patient (tumor sample FT-261 collected from the same patient) clustered in a group that contained ARMS tumor tissues, suggesting that tissue may bear tumorous genetic characters even with normal morphology and histology phenotype.
Next, we determined the functional significance of these differentially expressed genes between normal and RMS tissues using Ingenuity Pathway analysis (IPA). Notably, genes that are associated with muscle development and contraction were significantly downregulated in both RMS types compared with NSM. Conversely, genes implicated in neoplasia, cell division and tumorigenesis were overexpressed in both RMS compared with NSM ( Figure 2c ). We noticed upregulation of many cell cycle genes, including CCND2 and E2F7, in both ARMS and ERMS. CCND2 was the top-ranking gene in this analysis. The complete list of differentially expressed genes is given as Supplementary Information 4. As there are two predicted miR-1 or -206 binding sites within PAX3 3 0 UTR, reporter constructs were generated with mutations either in the first binding site (PAX3-3 0 UTRS1m-sGG), or the second binding site (PAX3-3 0 UTRS2m-sGG). Further, a construct with mutations in both sites miRNA gene regulatory network in rhabdomyosarcoma L Li et al (PAX3-3 0 UTRDum-sGG) was also generated. HEK293 cells were co-transfected with one of the above PAX3-3 0 UTR luciferase reporters along with miR-1 and/or -206 precursor. Wild-type PAX3-3 0 UTR showed decreased luciferase activity when co-transfected with miR-1 and /or -206. Constructs with mutations at site-1 or site-2 showed decreased luciferase activity similar to that of wild-type construct. Importantly, a construct with mutation at both site-1 and site-2 rescued the (Figure 3c ). These results indicate that both binding sites of miR-1 and -206 in PAX3 are functional and there is minimal preference between these binding sites. These data also suggests that there was no preferential selection between miR-1 and -206 to regulate PAX3 at least under the current experimental conditions. miR-1 and -206 Repress PAX3 Protein Expression in ERMS but not in ARMS We hypothesized that decrease in endogenous miR-1 and -206 in RMS may contribute to increased PAX3 expression. PAX3 is highly expressed in both ERMS and ARMS. However, in most ARMS, PAX3 forms a fusion transcript with FOXO1. It has been reported that PAX3 protein or PAX3-FOXO1 fusion protein contributes to tumorigenesis and outcome in RMS. 28 To (Figure 4b ). Therefore, we hypothesized that as miR-1 and -206 are significantly downregulated in RMS, the expression of CCND2 expression, similar to PAX3, may also be unrestricted in both RMS types. After transfecting miR-1 or -206 in JR1 and Rh30 cells, we tested CCND2 protein level using western blotting (Figure 4c ). In JR1, both miR-1 and -206 were very effective in decreasing CCND2 protein levels. However, in Rh30 cells, miR-206 was found to be more effective in repressing CCND2 levels than miR-1. Transfection efficiency and q expression of mature miR-1 and -206 in RMS cells were evaluated and confirmed using qRT-PCR (Supplemental Information 5, Supplementary Figure S2 ). It is noteworthy that compared with untransfected RMS cells, transfection with miRNA miR-1/ -206 precursors brought their levels up to B800-folds higher. miR-206 levels were comparable to physiological levels noticed in NSM, however levels of miR-1 in the transfected RMS cells were still significantly lower than NSM.
Cell Cycle Genes CCND2 and E2F7 are also Under the Regulation of miR-29
In addition to miR-1 and -206, our microarray and qRT-PCR data also showed significant downregulation of miR-29a, -29b and -29c (miR-29) in both ARMS and ERMS. Interestingly, miR-29 was predicted to target the cell cycle genes Cyclin D2 (CCND2) and E2F transcription factor 7 (E2F7) (Figure 5a ). In order to validate the regulation of these cell cycle genes by miR-29, we performed qRT-PCR in either JR1 or Rh30 cells exogenously expressing miR-29a, b or c. We observed significant downregulation of CCND2 transcript levels in both cell lines tested (Figure 5b, top panel) . We further confirmed this regulation at protein level by western blotting using antibodies against CCND2 in JR1 and Rh30 cells. Unlike CCND2 transcripts, which were significantly repressed by all miR-29 members in both cell lines, the regulation in CCND2 protein expression was specific to miR-29 family members (Figure 5d ). Whereas miR-29c significantly downregulated CCND2 expression in both JR1 and Rh30 Figure S3 ). Although CCND2 was previously shown to be a target for miR-29, 29 the interaction between miR-29 and E2F7 has not been experimentally validated. Hence, we carried out luciferase reporter assay to validate the direct interaction of miR-29 with E2F7. E2F7-3 0 UTR-sGG was co-transfected along with miR-29 a, b or c precursors in HEK293 cells. Construct with mutation in miR-29-binding site (E2F7-mut-sGG) served as control. Luciferase activities of wild-type E2F7-3 0 UTR vector were repressed when co-transfected with any of the miR-29 family miRNAs (Figure 5c ), whereas construct with mutation did not show any significant repression of luciferase activity. This suggests that miR-29a, -29b or -29c directly target E2F7 by binding to the 3 0 UTR in a sequencespecific manner (Figure 5c ).
Further, we validated the inverse correlation of miR-29 and E2F7 expression levels in JR1 and Rh30 with ectopic expression of miR-29. Our data show decreased E2F7 transcript levels only in JR1 cells (Figure 5b) . However, overexpression of miR-29a, b or c in Rh30 did not result in significant decrease in E2F7 transcripts. It may be possible that miR-29 regulation of E2F7 mediated at the protein translational level.
To investigate this further, we examined E2F7 protein expression in JR1, RD, Rh18 and Rh30 cells before and after transfection with either miR-29a, -29b or -29c. E2F7 protein was significantly repressed in both JR1 and Rh30 cells by miR-29a (Figure 5d ). We noticed similar effects on miR-29a/c in Rh18, however, there was no effect on E2F7 protein levels with these miRNAs in RD cells (Supplementary Information  5, Supplementary Figure S4) . Together, these experiments suggest that miR-29 family can exert both transcriptional and/or translational regulation of CCND2 and E2F7. Further, 
Ectopic Expression of miR-29 Regulates Cell Cycle and Proliferation in RMS Cells
As miR-29 family members are significantly downregulated in RMS and our data shows that miR-29 can regulate genes implicated in cell cycle, we functionally assessed the role of miR-29 in RMS cells transfected with individual and combined miR-29 a, b and c miRNA precursors. With individual transfection of miR-29 members, we noticed that JR1 cells showed G1 arrest (Figure 6a) . Consistently, combination of miR-29 a, b and c show significant G1 arrest in JR1 cells (Figure 6b ). miR-29 transfection also significantly inhibited proliferation of JR1 cells either individually or in combinations (Figure 6c) . We also noticed pro-apoptotic effect for miR-29 members transfected JR1 cells either individually (Figure 6d 
DISCUSSION
In this study, we have outlined a unique miRNA signature in RMS compared with NSM that potentially contributes to pathogenesis. Further, our microarray analyses showed that ARMS and ERMS are characterized by the presence of shared sets of miRNAs. For example, miR-183 was upregulated and miR-1, -206 and -29 were consistently downregulated in both ARMS and ERMS. These observations are in agreement with previous reports from other groups and our laboratory. [13] [14] [15] Recently, we showed that miR-183, which is upregulated in RMS, functions as an oncogene by targeting the transcription factor EGR1 and potentially have a role in tumor cell migration. This miR-183 network was also seen in other sarcoma such as synovial sarcoma, reiterating the presence of common deregulated miRNA networks in sarcomas. 23 Dysregulation of genes implicated in muscle differentiation is an important component of RMS pathogenesis. Our gene expression analysis in RMS patient samples showed downregulation of muscle differentiation genes and upregulation of genes implicated in various tumorigenesis functions. miRNAs including miR-1, miR-206 and miR-29 that are known to be associated with muscle development and differentiation 20, 30 are also significantly downregulated in RMS compared with NSM tissue. However, when compared with other sarcoma types, miR-1 and -206 are highly expressed in RMS tumors and cell lines, supporting the myogenic origin of RMS. In our miRNA microarray analysis, we also noticed that the probes for miR-1 and 206 were saturated due to high expression in the tumor tissues. 18 A recent study has shown that both miR-1 and -206 can be used as potential serum markers for RMS. 31 Here in this study, we show that miR-1 and -206 are potential regulators of PAX3 expression by binding to its 3 0 UTR. PAX3 have a critical role in myogenesis 32, 33 and increased expression of PAX3 is implicated in the pathogenesis of RMS. 34 Specifically, in ARMS, fusion transcript PAX3-FOXO1 produces a protein product, within which the structural integrity of both PAX3 DNA-binding regions, the paired box and homeodomain, are retained. However, the 3 0 UTR of PAX3 is lost during the formation of this functional fusion transcript 35 (Supplementary Information 5). In this context, the loss of 3 0 UTR region of PAX3 due to formation of fusion transcript may allow the fusion transcript PAX3-FOXO1 to escape miR-1, -206 or other potential miRNA-mediated regulation. A recent study also reported miRNA mediated regulation of PAX3. 36 A subset of ARMS is characterized by PAX7-FOXO1 translocation; a recent study has shown that both miR-1 and -206 can potentially regulate PAX7 in skeletal muscle satellite cells. 37 Based on these evidences, we propose that loss of 3 0 UTR of PAX3/PAX7 and /or the downregulation of miR-1 and -206 are oncogenic events in rhabdomyosarcomagenesis ( Figure 7) . In ERMS, although PAX3 is not associated with chromosomal translocation, we uncovered various PAX3 Figure 7c ). This suggests that the sequences adjacent to miRNA-binding sites in PAX3 may also have critical roles in miR-1/206 binding and regulation.
In our gene expression analysis of RMS patient samples, we also observed elevated expression of cell cycle genes such as CCND2. Elevated CCND2 levels are observed in various cancers and are implicated in cell proliferation. 38, 39 It was interesting to notice that miR-1 and -206 can also regulate CCND2 transcript and protein levels. Overexpression of miR-1 showed strong promyogenic effect in RMS cells and downregulated expression of CCND2 transcript levels. 40 As miRNAs can target and regulate several genes simultaneously, it is possible that downregulation of miR-1 and-206 allows the expression of CCND2 and other potential oncogenic targets in RMS leading to increased cell proliferation. Recently, it was shown that TGF-b inhibits differentiation of myogenic cells by downregulating miR-206 and -29 both of which targets HDAC4. 41 These findings reiterate that multiple miRNAs can cooperatively regulate genes involved in one or more cellular function/process. 
(ii)
(ii) Generation of both miRNA and mRNA expression profiles from the same set of RMS samples allowed us to investigate the correlation between miRNA and mRNA expressions. We investigated the negative correlation observed between miR-29 and cell cycle genes, including CCND2 and E2F7. One of the significantly downregulated miRNAs in both ARMS and ERMS is miR-29 family. miR-29 is implicated in cell functions such as proliferation, apoptosis and regulation of DNA methylation. 42, 43 A previous study has shown that miR-29 regulates myogenesis through feedback inhibition of YY1, an oncogene thus regulating cell proliferation. 15 In this study, we demonstrated that miR-29 targets both CCND2 and E2F7, genes involved in cell cycle control, and activates muscle differentiation genes such as alpha actin and myogenin (Supplementary Information 5, Supplementary Figure S8 ). CCND2 and E2F7 were upregulated in both RMS types and the inverse correlation between expression of miR-29 and these cell cycle genes suggest that miR-29 may function as a potential tumor suppressor in RMS by targeting these genes in addition to YY1. Thus, downregulation of miR-29 in both ARMS and ERMS allows stable expression of genes that have oncogenic potential. Consistent with the above observation, our cell cycle assay showed that ectopic expression of miR-29a, b or c caused cell cycle arrest at G1 phase in JR1 cells, which subsequently led to decreased proliferation in JR1 cells. A tumor suppressor role of miR-29 has been previously documented. 15, 43 Interestingly, overexpression of miR-29 in Rh30 had less effect on G1 arrest and proliferation. Studies have shown that E2F7 is essential for cell survival and embryonic development in mice and ectopic expression of E2F7 block cell cycle transition resulting in G1 arrest. 44, 45 As miR-29 regulates E2F7 expression, it is possible that presence of E2F7 in Rh30 allows cell proliferation even in the absence of CCND2. Taken together, these findings suggest that miR-29 family members may impart RMS cell type-specific function and /or require additional targets in mediating cellular functions.
Others and we have shown that miR-1, -206 and -29 are significantly downregulated in RMS. It is possible that these miRNAs are influenced by transcriptional regulation such as epigenetic alterations and/or loss of transcription factors. For example, MYOD, a transcription factor activates the expression of miR-1 and -206. However in RMS, it is non-functional due to the formation of inhibitory dimers. 8, 46 In addition, it has been shown that NF-kB and its target gene YY1 are highly expressed in RMS and epigenetically downregulate miR-29 b2/c. 15 In this study, we noticed that RMS cell lines showed variable responses to the ectopic expression of miR-1, -206 or -29. For example, RD cells showed decreased expression of PAX3 when transfected with miR-206, however Rh18 did not show any decreases in PAX3 with either miR-1 or -206. Further, protein expression of CCND2 and E2F7 were also modulated at different levels in these RMS cell lines with exogenous expression of miR-29 family members. These differential modulations of target genes results in varying levels of apoptosis or proliferation noticed in these RMS cell lines. As miRNA-mediated regulation of target genes are influenced by various factors such as p53 mutational status 43 and the presence of competing endogenous RNAs, 47 it is possible that presence or absence of these factors may influence the levels of PAX3 or CCND2 in these RMS cells.
All the four RMS cell lines studied have different genetic background; Rh30 is an ARMS with a characterized translocation t(2;13)(q35;q14) to form a fusion protein PAX3-FOXO1. Rh18 is also ARMS but without translocation. Both JR1 and RD are ERMS cell lines. In addition, these RMS cells also vary in their p53 mutational status. Unlike Rh18 that carries wild-type p53, point mutations in p53 were observed in JR1, RD and Rh30 cells. 48 As p53 activates several miRNAs such as miR-34a, p53 inactivation in JR1, RD and Rh30 may lead to differential expression of p53-activated miRNAs, which in turn may be required to target PAX3 or CCND2. For example, miR-29 could induce apoptosis in HCT116 (with wild-type p53) but not in p53-mutated SW480 colon cancer cell lines. 43 In addition, Muller Fabbri et al 42 observed significant reduction of DNMT3A levels with miR-29b, whereas no marked reduction was noticed with either miR29a or -29c, even though miR-29 members share the identical seed region.
In addition, these RMS cells were established from different patients with or without treatment. For example, Rh30 and Rh18 are derived from tumors obtained at the time of diagnosis, whereas JR1 and RD were from treated patients or with relapsed tumors. Another possible reason for differential regulation of miRNA target genes is the surrounding sequence in 3 0 UTR of the target genes. We have noticed deletions/mutations in PAX3 3 0 UTR in RMS tumor tissues from patient as well as cell lines, and our luciferase reporter assay shows that deletion of certain 3 0 UTR region causes more significant impairment for miR-1/206 binding to PAX3 3 0 UTR than the other regions examined. As multiple factors miRNA gene regulatory network in rhabdomyosarcoma L Li et al influences miRNA regulation of target genes, it is difficult to pinpoint specific mechanism that cause differential regulation of PAX3, CCND2 or E2EF7 expression in RMS cells treated with miRNAs.
In conclusion, ARMS and ERMS are characterized by miRNAs that are commonly deregulated in both types. miR-1 and -206 are downregulated in RMS tumors and cell lines that lead to stabilization of two potential oncogenes PAX3 and CCND2. Further, loss of 3 0 UTR of PAX3 during the formation of fusion transcript or even loss of sequence adjacent to miRNA-binding sites may be an oncogenic mechanism to evade miR-1-and -206-mediated repression. Also, miR-29, which is downregulated in both RMS types, targets cell cycle genes CCND2 and E2F7 and may potentially function as a tumor suppressor. Taken together, our study suggests the presence of multiple deregulated miRNA networks in RMS and the RMS state is stabilized by the deregulation of multiple miRNAs and their target genes, supporting a tumor suppressor role for these miRNA.
